Filament Health Corp (NEO:FH, OTCQB:FLHLF), a natural psychedelic drug development firm, reports successful voting results at its Annual General Meeting (AGM). Shareholders overwhelmingly approved all resolutions, with 40.28% of issued Common Shares represented. All director nominees, including Ben Lightburn, Chris Wagner, Jon Conlin, Maureen O'Connell, and Konstantin Adamsky, were elected. Shareholders also approved maintaining a board of five directors and authorized the directors to determine the auditor's remuneration.
The Markets by Proactive
Go to Proactive Australia
Proactive’s Australian coverage continues on .com